ClinicalTrials.Veeva

Menu

An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

Kansas Board of Regents logo

Kansas Board of Regents

Status

Completed

Conditions

Breast Cancer

Treatments

Drug: letrozole 2.5 mg

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole

Full description

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products (PCNA, cyclin-D1, ER alpha, PR, pS2, 450 aromatase, bcl-2, bax, caspase-3, and VEGFR) that may be useful as predictors or indicators of response to letrozole

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast
  • on hormone replacement therapy
  • postmenopausal
  • increased risk of developing breast cancer based on personal or family history
  • never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months
  • women who have a high risk of breast cancer
  • older than 18 years

Exclusion criteria

  • no anticoagulants
  • no marked breast tenderness
  • not pregnant or within twelve months of breast feeding/childbirth

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems